The global respiratory distress syndrome management market is slated to reach a valuation of US$ 115.4 billion in 2023. According to Future Market Insights, the market is expected to grow at a 4.41% CAGR until 2033, valued at US$ 177.7 billion. Also, according to the recent study by FMI, it is noted that the industry sponsors will be leading the market with an expected share of about 54.7% in the year 2023, within the global market.
Several factors that can drive the market growth such as improved healthcare facilities with an increase in research and drug development for the treatment, technological advancements in the treatment & increase in healthcare investment day by day will lead to profitable growth opportunities in the forecast period.
This global respiratory distress syndrome treatment is a serious life-threatening viral infection including symptoms like cough, chills and shaking, headache, etc is said to be transferrable from one person to another in a short period. In October 2012, this infection was added to National Select Agent Registry, regulating the handling and control of bacteria and virus that is said to cause severe risk to the public’s health and safety.
The development of the global respiratory distress syndrome treatment may be restrained due to a lack of qualified and experienced specialists who have no idea of the treatment available for this illness can restraint the growth of the market during the forecast period. Moreover, Limited approved drugs for the treatment also inhibited the growth of the market.
Antivirals and antibiotics are generally recommended for the treatment of this respiratory distress syndrome treatment. But in many cases, antibiotic treatment is alone not enough for the treatment, supportive care is also required.
| Attributes | Details |
|---|---|
| Base year Market Value (2022) | US$ 110.3 billion |
| Projected Forecast Value (2023) | US$ 115.4 billion |
| Projected Forecast Value (2033) | US$ 177.7 billion |
| Growth rate | 4.41% |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global respiratory distress syndrome management market grew at a CAGR of 4.24% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Historically, the focus of mechanical ventilation in respiratory failure has been to maintain adequate oxygenation and carbon dioxide elimination where several preclinical studies indicated that the common clinical practice of using relatively high tidal volumes and elevated airway pressures for ARDS patients might exacerbate the degree of lung injury.
In the year 2000, investigators supported by the US National Heart Lung and Blood Institute ARDS Network completed a randomized phase III clinical trial in which a tidal volume of 6 ml per kg PBW, compared with the more common higher tidal volume of 12 ml per kg PBW, improved survival, shortened duration of mechanical ventilation, attenuated systemic inflammation and accelerated recovery of extra-pulmonary organ failures, and the biologic findings were reported in other studies. Thus, with the discovery of the major role that mechanical forces play in the pathogenesis of lung injury, optimizing ventilator support to minimize VALI has become central to the clinical management of ARDS, leading to the concept of lung-protective ventilation.
The recently developed Radiographic Assessment of Lung Edema (RALE) score may be a novel tool to predict severity, outcomes, and response to therapy in ARDS. In the derivation cohort of this study, the RALE score was correlated with lung weight from excised lungs in deceased organ donors 3. Before the widespread use of this score, extensive validation is required. The use of lung ultrasound for the diagnosis of ARDS may be a promising tool but needs further study. Sensitive and specific biomarkers of ARDS, if available, may aid in earlier and more accurate diagnosis. Also, Future investigations should refine clinical, radiographic, physiological, molecular, and genetic differences in phenotypes to better understand the pathobiology of ARDS and develop novel therapies.
The rising incidence of clinical trials is driving growth
Increasing research and development and clinical trials and usage of therapeutics for the respiratory distress syndrome management market will eventually propel the growth of the market. Government initiatives taken to the reduction in mortality rate will also be a major factor that will help in the contribution of the growth of the market.
Increasing prevalence and incidence of acute lung injury
The increasing alcohol consumption, irrespective of age, leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.
The rising rate of air pollution and lifestyle-related diseases
The World Health Organization, air pollution is one of the greatest environmental risks to health by increasing the burden of diseases like heart diseases and lung and respiratory infections at both acute and chronic levels. Hence, the rising air pollution rate in developed and developing countries increases the chances of people getting syndromes like acute respiratory distress syndrome. Thus, the factor is expected to drive the growth of the market.
Increasing accident rates and trauma causing ARDS
The inhalation of smoke releases materials like fibrin, neutrophils, mucus, and epithelial cell debris that occlude the airway lumen, causing changes in ventilation. This condition leads to hypoxemia which is a primary significant reason for ARDS. They also reported that increased mortality rates in burn patients were due to ARDS. Thereby, the rising number of accidents and trauma injuries in the lungs is expected to drive the growth of the market.
Principal Consultant
Complications associated with treatments
There are treatments for ARDS helping people survive, but the complications associated with treatments and post-treatment are still a burden for patients. Most potential and lasting effects include breathing problems, depression, problems with memory and thinking, tiredness and muscle weakness, and more.
These complications associated with and post-treatment of acute respiratory distress syndrome are expected to hamper the market growth during our forecast period.
High cost of device and treatments
The high cost of ventilation treatment per day is not affordable if the therapy has to proceed for many days. Hence patients prefer taking ventilators for home care. However, the price of ventilators is yet quite expensive. Therefore, the high cost of treatment and ventilators is very challenging for people to afford any reliable remedy for the long term until the patient completely recovers. This is anticipated to hamper the growth of the market.
The hospital segment in North America is expected to grow with the highest growth rate
The countries covered in the acute respiratory distress syndrome (ARDS) market report are USA., Canada, and Mexico. In the forecast period of 2023 to 2033 because of increasing government and organizational support.
The hospital segment in Canada is second dominating the market owing to increasing cases of chronic respiratory diseases and high adoption of proper diagnosis. Mexico is third leading the growth of the market and the hospital segment is dominating in this country due to the increasing number of new hospital infrastructures being opened due to the emergence of COVID-19.
Increasing technological advancement in the country
The parenteral segment in Japan is expected to grow with the highest growth rate in the forecast period of 2023 to 2033 because of increasing technological advancement in the country.
The parenteral segment in China is second dominating the market owing to increasing cases of chronic respiratory diseases and high adoption of proper diagnosis. South Korea is third leading the growth of the Asia-Pacific market and the parenteral segment is dominating in this country due to the increasing number of biotechnologies centers and research activities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The nasal segment will gain the dominant market share
Advancements in neonatal care have been driving growth as the survival rate of premature infants with RDS has increased due to improved diagnostic methods and treatments thus fuelling demand. Various leading companies like Smiths Medical offers neonatal care products, including neonatal ventilators and respiratory support devices.
Also, babies have survived longer and with less lung damage due to the introduction of volume-targeted ventilators as they require support for shorter periods leading to a low risk of developing pneumothorax.
The demand for hospital pharmacies will be more during the forecast period.
According to a report by Future Market Insights, the hospital pharmacies would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.
Due to the rise in population and advancement in technologies, a growing number of people are more prone to visiting hospitals for advice on respiratory distress syndrome management market treatment-related, where they will be provided not only with proper care but also with the new and advanced level of instruments at each interval of time. As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
The start-ups in this sector aim to use several techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.
Some of the prominent players in the global market for RDS treatment are
Some of the important developments of the key players in the market are
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4.41% from 2023 to 2033 |
| Market value in 2023 | US$ 115.4 Billion |
| Market value in 2033 | US$ 177.7 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
Drug class, Route of Administration, End-user, Region |
| Regions Covered |
North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled |
United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Companies Profiled |
JW Pharmaceutical; Windtree Therapeutics, Inc.; ONY Biotech Inc; AbbVie Inc.; Teva Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; GlaxoSmithKline plc.; Pfizer Inc.; Gilead Sciences, Inc.; Hoffmann-La |
| Customisation Scope | Available on Request |
The growth potential of the market is 4.41% through 2033.
Complication in treatment is likely to limit market growth.
Rising technological advancements are fueling Japan’s growth by 2033.
The market is estimated to get a valuation of US$ 115.4 billion in 2023.
Canada, the United States, and Japan may witness significant growth in the market.
1. Executive Summary | Respiratory Distress Syndrome Management Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Vasoconstrictors 5.2. Bronchodilators 5.3. Steroids and Antibiotics 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Parenteral 6.3. Nasal 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 7.1. Hospital pharmacy 7.2. Online pharmacy 7.3. Retail pharmacy 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. JW Pharmaceutical 18.2. Windtree Therapeutics, Inc. 18.3. ONY Biotech Inc. 18.4. AbbVie Inc. 18.5. Teva Pharmaceutical Industries Ltd. 18.6. Takeda Pharmaceutical Company Limited 18.7. GlaxoSmithKline plc. 18.8. Pfizer Inc. 18.9. Gilead Sciences, Inc. 18.10. Hoffmann-La Roche Ltd 18.11. Fresenius Kabi AG 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
January 2023
REP-GB-2345
250 pages
Explore Healthcare Insights
View Reports
Respiratory Distress Syndrome Management Market
